Markowitz et al. reported that the depletion of CD4+ and/or CD8+ T cells combined with an anti-programmed cell death 1 (PD1) antibody reduces the therapeutic efficacy of the PD1 blockade in a KRAS-driven mouse model of NSCLC [13]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.